Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY: BSX )

95.52 +1.39 (+1.48%)
Official Closing Price Updated: 7:00 PM EDT, Mar 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes
Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected. 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Reasons to Like BSX (and 1 Not So Much)
Since March 2020, the S&P 500 has delivered a total return of 97.5%. But one standout stock has nearly doubled the market - over the past five years, Boston Scientific has surged 176% to $97 per share.... 
Via StockStory
Topics Stocks
Exposures US Equities
ResMed Among Top Stocks For Recent And Long-Term Profit Growth
A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue? 
Via Investor's Business Daily
What To Expect From CooperCompanies’s (COO) Q4 Earnings
Medical device company CooperCompanies (NASDAQ:COO) will be reporting results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Beyond The Numbers: 17 Analysts Discuss Boston Scientific Stock
Via Benzinga
$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
Via Benzinga
What Does the Market Think About Boston Scientific?
Via Benzinga
Why the high growth investor may take a look at BOSTON SCIENTIFIC CORP (NYSE:BSX).
Should you consider BOSTON SCIENTIFIC CORP (NYSE:BSX) for high growth investing? A fundamental and technical analysis of (NYSE:BSX). 
Via Chartmill
Boston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio
Boston Scientific will acquire SoniVie for up to $600 million on 100% basis, adding the TIVUS ultrasound system to its hypertension treatment pipeline. Deal closes in H1 2025. 
Via Benzinga
1 Growth Stock with All-Star Potential and 2 to Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
Exposures COVID-19
Top Stock Reports For Goldman Sachs, Progressive & Boston Scientific
Today's Research Daily features new research reports on 16 major stocks, including The Goldman Sachs Group, Inc., The Progressive Corp. and Boston Scientific Corp., as well as micro-cap stock... 
Via Talk Markets
Topics Stocks / Equities
Medical Devices & Supplies - Diversified Stocks Q4 Teardown: Stryker (NYSE:SYK) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified... 
Via StockStory
Which S&P500 stocks are moving on Tuesday?
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Q4 Earnings Roundup: Baxter (NYSE:BAX) And The Rest Of The Medical Devices & Supplies - Diversified Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4,... 
Via StockStory
Q4 Earnings Highs And Lows: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQ:NEOG) and its peers. 
Via StockStory
UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside
Via AB Newswire
Baxter Earnings: What To Look For From BAX
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
What To Expect From Baxter’s (BAX) Q4 Earnings
Healthcare company Baxter International (NYSE:BAX) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
ResMed Getting Close To Elite Stock Group Entry
ResMed also boasts a 93 Composite Rating. The best growth stocks often have a 90 or higher Composite as they begin their biggest runs. 
Via Investor's Business Daily
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best... 
Via StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 Billion
GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 billion in sales. 
Via Investor's Business Daily
Boston Scientific Beats Its Own Fourth-Quarter Guidance On Cardiovascular Strength
Boston Scientific stock dipped Wednesday, but the medtech company beat Wall Street's fourth-quarter forecasts. 
Via Investor's Business Daily
Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations
Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87. 
Via Benzinga
Zimmer Biomet (ZBH) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Zimmer Biomet (NYSE:ZBH) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
BD (BDX) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for. 
Via StockStory
Earnings To Watch: Haemonetics (HAE) Reports Q4 Results Tomorrow
Blood products company Haemonetics (NYSE:HAE). will be announcing earnings results tomorrow before the bell. Here’s what to expect. 
Via StockStory
Boston Scientific (NYSE:BSX) Reports Bullish Q4, Guides for Strong Sales Next Quarter
Medical device company Boston Scientific (NYSE:BSX) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 22.4% year on year to $4.56 billion. Guidance for next quarter’s... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.